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Abstract
Objective To compare the effectiveness of social behaviour and
network therapy, a new treatment for alcohol problems, with
that of the proved motivational enhancement therapy.
Design Pragmatic randomised trial.
Setting Seven treatment sites around Birmingham, Cardiff, and
Leeds.
Participants 742 clients with alcohol problems; 689 (93.0%)
were interviewed at three months and 617 (83.2%) at 12
months.
Interventions Social behaviour and network therapy and
motivational enhancement therapy.
Main outcome measures Changes in alcohol consumption,
alcohol dependence, and alcohol related problems over 12
months.
Results Both groups reported substantial reductions in alcohol
consumption, dependence, and problems, and better mental
health related quality of life over 12 months. Between groups
we found only one significant difference in outcome, probably
due to chance: the social network group showed significantly
better physical health at three months. Non-significant
differences at 12 months in the motivational group relative to
the social network group included: the number of drinks
consumed per drinking day had decreased by an extra 1.1 (95%
confidence interval − 1.0 to 3.2); scores on the Leeds
dependence questionnaire had improved by an extra 0.6 ( − 0.7
to 2.0); scores on the alcohol problems questionnaire had
improved by an extra 0.5 ( − 0.4 to 1.4); but the number of days
abstinent from drinking had increased by 1.2% less ( − 4.5% to
6.9%).
Conclusion The novel social behaviour and network therapy
for alcohol problems did not differ significantly in effectiveness
from the proved motivational enhancement therapy.
Introduction
Alcohol dependence and misuse are common and costly. In
2000 the estimated prevalence of alcohol dependence in the
United Kingdom was 11.9% among men and 2.9% among
women.1 The public costs of heavy drinking in England and
Wales are about £18 000m ($32 438m; €26 424m).2 Some 300
advice and counselling services, 100 day programmes, and
nearly 200 residential programmes meet the resulting demand
for treatment.3
No British randomised trial of non-pharmacological
treatments for alcohol problems has had the statistical power to
detect even medium sized effects.4 To our knowledge only one
randomised trial (the “matching alcoholism treatments to client
heterogeneity” trial) of psychosocial treatments for alcohol
problems has been able to detect small effects, by studying 1726
clients in nine treatment sites across the United States.5 Clients
were randomly allocated to three manual based interventions,
namely cognitive behavioural therapy, twelve step facilitation
therapy, and motivational enhancement therapy. Cognitive
behavioural therapy and twelve step facilitation therapy each
comprised 12 sessions whereas the motivational enhancement
therapy comprised four sessions, all over 12 weeks. Results
showed substantial improvements in drinking outcomes for all
three. Motivational enhancement therapy achieved outcomes
essentially similar to those of the two more intensive
treatments.5 6 The size of the trial meant that this was unlikely to
have been a type 2 error.
This evidence and the increasing popularity of motivational
enhancement therapy led to the proposal that this therapy
should act as standard treatment in research on the effectiveness
of treatment for alcohol problems.7 Meta-analyses have since
confirmed the effectiveness of such treatments.8 These
arguments led us to propose—and the Medical Research Coun-
cil to accept—that motivational enhancement therapy should act
as reference treatment within the United Kingdom alcohol treat-
ment trial (UKATT).9 For ethical reasons we excluded a “no
treatment” control group because we did not want to deprive
participants of the known benefits of treatment.
To build on the US trial we exploited systematic reviews
citing effective treatments that considered clients’ social environ-
ment and support system.10 We designed and tested the social
behaviour and network therapy specifically for our trial.11 The
underlying theory is that overcoming alcohol problems needs
support from family or friends. Thus we compared a novel social
treatment with a strong theoretical and empirical basis with an
established but briefer motivational treatment of proved
effectiveness.
Methods
We carried out a pragmatic randomised trial in seven UK sites
around Birmingham, Cardiff, and Leeds to test two main null
hypotheses9 that socially based treatment (social behaviour and
network therapy) and briefer, motivationally based treatment
(motivational enhancement therapy) are equally effective and
equally cost effective, notably in improving clients’ quality of life
(reported in the accompanying economic paper).12
The corresponding alternative hypotheses were both two
sided. We were keen to derive recommendations for clinical
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practice from the trial. With little research in this field we were
open to recommend either therapy as the treatment of choice. If
the therapies were similar in effectiveness and cost effectiveness,
we were open to recommend that choice should depend on
other factors, perhaps local.
Interventions
The sites nominated 76 candidates to train as therapists for the
trial. To demonstrate suitability for training, the candidates
submitted separate video recordings showing motivational skills
and ability to work with clients’ family and friends. We randomly
assigned roughly twice as many therapists to the social behaviour
and network therapy as to motivational enhancement therapy
because social therapy takes about twice as much therapist time
as motivational therapy. We trained 72 of the candidates in their
allocated treatments through courses at Leeds lasting three days.
To achieve accreditation, the trainees had to complete the super-
vised treatment of one or two clients and show competence
through video recordings. The 52 therapists who achieved this
continued to record treatment sessions on video and to receive
supervision to encourage compliance with their allocated
manual.
To cater for needs not addressed by the treatments, to clients
awaiting randomisation we offered alcohol detoxification,
treatment of organic disease, attention to emergency housing
needs, and advice on financial matters.9
Social behaviour and network therapy
Social behaviour and network therapy comprises cognitive and
behavioural strategies to help clients build social networks
supportive of change.11 In our trial the therapy comprised eight
50 minute sessions over eight to 12 weeks.
Motivational enhancement therapy
In our trial, motivational enhancement therapy comprised three
50 minute sessions over eight to 12 weeks.9 It combined counsel-
ling in the motivational style13 with objective feedback.14 The
therapy showed two main changes from the version used in the
US study,14 both designed to keep it distinct from social
behaviour and network therapy while retaining the features that
led to the proposal that it act as standard treatment in research
on treatment for alcohol problems.7 8 Firstly, we offered three
sessions rather than four. Secondly, we allowed “significant
others” to attend only the first session and to provide only con-
firmatory information.
Inclusion and exclusion criteria
We sought to include clients who would normally receive an
offer of treatment from British treatment sites for alcohol prob-
lems.9 We excluded people aged under 16; people who were illit-
erate, could not name a contact, or intended to leave the area;
people with uncontrolled psychotic illness or severe cognitive
impairment; people for whom alcohol was not the main
problem; and people who were receiving treatment for an alco-
hol problem.
Screening, randomisation, and follow-up
Clinical staff screened clients for eligibility.9 Potential partici-
pants were interviewed by the researchers to confirm eligibility
and to gain written informed consent. The remote randomisa-
tion service at York used a computer “on line” to allocate
consenting participants between therapy groups, stratified by
site. Treatment was concealed until allocation. To make best use
of available slots the service allocated clients between therapies
with probabilities proportional to the numbers of slots currently
available for those treatments in the client’s site.9
Researchers interviewed participants at home three and 12
months after entry to the trial, regardless of whether treatment
was completed.9 Both schedules were similar to those completed
before treatment. At 12 months we employed a new team of
interviewers to ensure that they were blind to treatment
allocation. We did not have the resources to do this at three
months.
Outcome measures
Primary outcome measures were9 alcohol consumption, derived
from form 9015 and summarised by number of drinks (that is,
units of alcohol, equivalent to 8 g of ethanol) per drinking day
and percentage of days abstinent5; alcohol dependence,
measured by the Leeds dependence questionnaire16; alcohol
related problems over the past three months, measured by the
alcohol problems questionnaire17; and -glutamyl transferase, a
liver function test measured by the Reflotron18—although this
test is better used to monitor change after an abnormal score, it
reputedly corroborates reported alcohol consumption.
Secondary outcome measures were associated with health
related quality of life9: the EQ-5D, a commonly used health status
index19; the SF-36, a commonly used health profile20; and the
general health questionnaire 28,21 commonly used to measure
psychological disturbance.
Sample size
We aimed to recruit 720 clients at seven sites.9 We sought to
interview 80% of these after 12 months. Allowing for correlation
Table 1 Participant characteristics at randomisation. Values are numbers
(percentages) unless stated otherwise
Categorical characteristics
Motivational
group
Social
behaviour group Total
n=422 n=320 n=742
Mean (SD) age (years) 41.8 (10.1) 41.4 (10.0) 41.6 (10.1)
Men 315 (74.6) 235 (73.4) 550 (74.1)
White 406 (96.2) 303 (94.7) 709 (95.6)
Education:
Degree or equivalent 45 (10.7) 29 (9.1) 74 (10.0)
No qualifications 272 (64.5) 205 (64.1) 477 (64.3)
Marital status: n=422 n=319 n=741
Married, living with partner 167 (39.6) 123 (38.6) 290 (39.1)
Married, not living with partner 15 (3.6) 23 (7.2) 38 (5.1)
Single, in current relationship 60 (14.2) 51 (16.0) 111 (15.0)
Single, not in current
relationship
180 (42.7) 122 (38.2) 302 (40.8)
Employment: n=420 n=319 n=739
Employed 152 (36.2) 105 (32.9) 257 (34.8)
Sick or disabled 146 (34.8) 106 (33.2) 252 (34.1)
Unemployed 96 (22.9) 86 (27.0) 182 (24.6)
Retired 22 (5.2) 16 (5.0) 38 (5.1)
Non-employed 4 (1.0) 6 (1.8) 10(1.4)
Reported annual income: n=410 n=314 n=724
>£20 000 73 (17.8) 64 (20.4) 137 (19.0)
£15 001-£20 000 45 (11.0) 20 (6.4) 65 (9.0)
£10 001-£15 000 57 (13.9) 41 (13.1) 98 (13.5)
£5001-£10 000 88 (21.5) 63 (20.1) 151 (20.9)
<£5000 147 (35.9) 126 (40.1) 273 (37.7)
Goals reported at recruitment: n=422 n=320 n=742
To abstain 226 (53.6) 177 (55.3) 403 (54.3)
To abstain through disulfiram* 62 (14.7) 67 (20.9) 129 (17.4)
To use acamprosate† 85 (20.1) 58 (18.1) 143 (19.3)
Detoxification‡ 107 (25.4) 104 (32.5) 211 (28.4)
*Creates expectation that drinking results in unpleasant reaction between alcohol and drug.
†Suppresses craving for alcohol.
‡Done between screening and recruitment.
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within sites and for the minor imbalance in the number of clients
allocated to each therapy resulting from the corresponding
imbalance in the numbers of therapists, our trial had at least 80%
power using a 5% significance level to detect a standardised dif-
ference, either positive or negative, of less than one quarter (usu-
ally regarded as a small effect) between the therapies.
Statistical analysis
In accordance with our prespecified analysis plan we used analy-
sis of covariance to take account of site (prestratification factor),
use of detoxification, and drinking goal as reported at randomi-
sation (poststratification factors) and to adjust for differences
between groups in scores before randomisation. We analysed
data by intention to treat. To assess whether attrition affected
findings we undertook sensitivity analysis using the last recorded
response from each respondent (last observation carried
forward).
Results
Between 1999 and 2001 we recruited 742 participants with alco-
hol problems (figure) from clients of all ages above 16 and all
social groups (table 1). Although only 211 (28.4%) received
detoxification between screening and recruitment (table 1), oth-
ers had done so before screening, when levels of dependency
were probably higher. We interviewed 689 (93.0%) participants
at three months and 617 (83.2%) at 12 months (table 2). Of 125
participants lost to follow-up at 12 months, 12 had died, 35 did
not respond, and 78 could not be traced or contacted.
Analysis of covariance showed that the therapy groups
achieved similar outcomes at three and 12 months (table 3). As
attrition was only 7% at three months and 17% at 12 months,
sensitivity analysis using the last observation carried forward
generated similar findings. The only significant difference we
found was that after three months the adjusted mean physical
component score of the SF-36 for clients in the social network
group exceeded that of the clients in the motivational group by
1.31 (95% confidence interval 0.05 to 2.57). As both mean scores
were close to those at baseline (table 2), and because we invoked
18 distinct significance tests (table 3), it would be prudent to
regard this as a possible random consequence of multiple com-
parisons.
To explore these findings further, we compared the mean
adjusted scores at baseline and after three and 12 months for all
who responded (table 2). At three months we found highly
significant improvements in all patient outcomes except the
EQ-5D and log -glutamyl transferase. Baseline correlations
between log -glutamyl transferase and patient assessed
outcomes were, however, all 0.3 or less.
The adjusted proportion of days on which clients reported
that they had abstained improved from 29% to 43% at three
months and to 46% at 12 months. Mean adjusted alcohol
consumption reported by continuing drinkers fell from 27
Table 2 Mean (95% confidence intervals) adjusted scores for primary and secondary outcomes across social behaviour group and motivational group
combined at baseline and three and 12 months
Outcome measures Baseline (n=742) 3 months (n=689) 12 months (n=617)
Days abstinent (%) 29.5 (26.1 to 32.9) 42.7 (38.2 to 47.2) 46.0 (40.8 to 51.2)
No of drinks* per drinking day 26.8 (24.9 to 28.7) 17.9 (16.3 to 19.5) 19.2 (17.2 to 21.2)
Log -glutamyl transferase 4.01 (3.86 to 4.16) 3.89 (3.77 to 4.01) 4.00 (3.83 to 4.17)
Leeds dependence questionnaire 17.0 (15.9 to 18.1) 11.9 (10.8 to 13.0) 10.9 (9.6 to 12.2)
Alcohol problems questionnaire† 12.3 (11.7 to 12.9) 6.8 (6.1 to 7.5) 6.1 (5.3 to 7.0)
EuroQol (EQ-5D) 0.574 (0.534 to 0.614) 0.629 (0.592 to 0.666) 0.607 (0.562 to 0.652)
General health questionnaire 28 40.0 (37.6 to 42.4) 31.2 (28.7 to 33.7) 29.9 (27.0 to 32.8)
SF-36:
Mental component 29.7 (28.0 to 31.4) 36.6 (34.6 to 38.6) 38.7 (36.5 to 40.9)
Physical component 45.4 (44.0 to 46.8) 48.0 (46.8 to 49.2) 47.6 (46.2 to 49.0)
Adjusted by analysis of covariance for centre, use of detoxification, and three goals reported at randomisation (to abstain, to abstain through disulfiram, and to use acamprosate); and
corresponding baseline score for outcomes at 3 and 12 months.
*Units of alcohol, equivalent to 8 g of ethanol.
†Common items.
Table 3 Mean (SE) adjusted scores for primary and secondary outcomes by allocated treatment at three and 12 months
Outcomes measures
3 months 12 months
Motivational group Social network group
Difference in favour of
social group (95% CI) Motivational group Social network group
Difference in favour of
social group (95% CI)
Days abstinent (%) 42.3 (2.56) (n=393) 43.2 (2.63) (n=293) 0.90 (−3.98 to 5.78) 45.4 (2.98) (n=351) 46.6 (3.06) (n=261) 1.19 (−4.50 to 6.88)
No of drinks per drinking day 17.6 (0.89) (n=361) 18.2 (0.92) (n=263) −0.53 (−2.22 to 1.17) 18.7 (1.11) (n=303) 19.8 (1.15) (n=217) −1.14 (−3.22 to 0.95)
Log -glutamyl transferase 3.87 (0.070) (n=331) 3.90 (0.070) (n=259) −0.033 (−0.163 to 0.097) 4.01 (0.0941) (n=293) 4.00 (0.0992) (n=214) 0.010 (−0.170 to 0.189)
Leeds dependence questionnaire
(0-30, 0=best)
12.0 (0.65) (n=367) 11.8 (0.67) (n=275) 0.24 (−0.99 to 1.46) 10.6 (0.728) (n=332) 11.2 (0.766) (n=231) −0.64 (−2.02 to 0.74)
Alcohol problems questionnaire
(0-23, 0=best)
6.85 (0.41) (n=371) 6.79 (0.42) (n=280) 0.06 (−0.71 to 0.83) 5.90 (0.467) (n=326) 6.38 (0.489) (n=233) −0.48 (−1.36 to 0.40)
EQ-5D (<0 to 1, 1=best) 0.631 (0.021)
(n=359)
0.626 (0.022)
(n=272)
−0.005 (−0.045 to 0.035) 0.623 (0.025) (n=317) 0.592 (0.026) (n=230) −0.031 (−0.079 to 0.016)
General health questionnaire 28
(0-84, 0=best)
31.6 (1.43) (n=364) 30.9 (1.47) (n=274) 0.71 (−1.98 to 3.40) 28.6 (1.63) (n=324) 31.2 (1.72) (n=234) −2.64 (−5.73 to 0.44)
SF-36 (mean 50, SD 10,
higher=better):
Mental component 36.9 (1.11) (n=341) 36.3 (1.12) (n=263) −0.56 (−2.63 to 1.50) 39.5 (1.26) (n=299) 37.9 (1.30) (n=221) −1.56 (−3.88 to 0.76)
Physical component 47.3 (0.68) (n=341) 48.6 (0.69) (n=263) 1.31 (0.05 to 2.57) 47.2 (0.80) (n=299) 47.9 (0.82) (n=221) 0.68 (−0.79 to 2.16)
Adjusted by analysis of covariance for corresponding baseline score, centre, use of detoxification, three goals reported at randomisation (to abstain, to abstain through disulfiram, and to use
acamprosate.
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drinks per drinking day to 18 at three months and to 19 at 12
months. Reported mean adjusted scores on the Leeds
dependence questionnaire fell from 17 to 12 at three months
and to 11 at 12 months. Reported mean adjusted scores on the
alcohol problem questionnaire fell from 12 to 7 at three months
and to 6 at 12 months. Reported mental health also improved:
the mean adjusted score of the mental component of the SF-36
rose from 30 to 37 at three months and to 39 at 12 months. We
found no serious adverse events.
Discussion
Social behaviour and network therapy (a novel social treatment
for alcohol problems) and motivational enhancement therapy (a
motivational treatment of proved effectiveness), led to similar
improvements in reported alcohol consumption, dependence,
and problems, and in mental health, all of which were
maintained over 12 months. Clients in both groups reported that
total alcohol consumption had decreased by 48% at three
months and by 45% at 12 months and that alcohol related prob-
lems had decreased by 44% at three months and by 50% at 12
months.
By recruiting more than 700 participants, our trial had power
to detect small differences. Our trial was pragmatic in that it
compared the effectiveness of treatments under routine
conditions rather than their efficacy under controlled conditions.
Internal validity was protected, notably by randomising
therapists between therapies, randomising clients remotely, and
keeping interviewers blind to treatment at 12 months.9 Since we
treated motivational enhancement therapy as a reference
treatment of proved effectiveness, we infer that social behaviour
and network therapy is equally effective.
The intrinsic effects of the therapies may be less than those
reported, however, for four reasons. Firstly, the scientific rigour
with which the trial design protected internal validity may have
reduced external validity. Secondly, some improvement may
have been due to regression to the mean. Thirdly, some
improvement may have been the result of response bias. Finally,
log -glutamyl transferase, a test correlated with alcohol
consumption, changed little over 12 months. However, this test
adds little to careful history taking in clinical practice,22 and the
US “matching alcoholism treatments to client heterogeneity”
trial showed that it added little to self report in clinical trials.23
There are three other reasons for believing that the intrinsic
effects of both therapies are real and sustained. Firstly, as there
were three distinct steps between participants’ attendance with a
new alcohol problem and the baseline measurements that
preceded randomisation (namely screening, referral, and
interview; figure), bias due to regression to the mean is less likely
to occur between baseline and subsequent measurements.
Secondly, our participants consistently reported substantial
reductions in alcohol consumption and consequent problems
lasting at least 12 months. Finally, natural recovery from alcohol
problems does occur but comparisons of treated and untreated
samples imply that alcohol dependent individuals benefit from
treatment.24 Furthermore, evidence from trials shows that it is the
intrinsic effect of motivational enhancement therapy rather than
the non-specific effect of intervening that is responsible for its
benefits.25
We can identify two main reasons why we found little differ-
ence between the therapies. Firstly, the evidence for the validity
of self reports22 23 and the evidence from outside our trial for the
effectiveness of motivational enhancement therapy6–8 24 25
strongly suggest that both therapies are effective. Secondly, both
therapies add three common elements to the treatment process:
a structured, published manual based on available scientific evi-
dence; training of therapists at the Leeds Addiction Unit in a
professional and rigorous atmosphere; and regular supervision
of the therapists by separate teachers with considerable
experience of treatment for alcohol problems. Hence therapists
expected both therapies to yield good results.
In a separate economic paper we investigate the cost
effectiveness of the therapies.12 Both social behaviour and
network therapy and motivational enhancement therapy proved
acceptable to clients, managers, and more than 50 therapists
allocated between them at random. More importantly, our
Clients attending sites with new alcohol problem (n=3241)
Not screened (n=493, 15.2%)
Screened (n=2748, 84.4%)
Refused (n=1157, 42.1%)
Ineligible (n=650, 23.7%)
Referred to trial entry interview (n=941, 34.2%)
Did not attend interview (n=105, 11.2%)
Attended trial entry interview (n=836, 88.8%)
Randomised (n=742, 88.8%)
Social behaviour and network
therapy (n=320, 43.1%)
Motivational enhancement
therapy (n=442, 56.9%)
Completed three month
assessment (n=393, 93.1%)
Completed 12 month
assessment (n=352, 83.4%)
Completed three month
assessment (n=296, 92.5%)
Completed 12 month
assessment (n=265, 82.8%)
Allocated to training or withdrew consent (n=94, 11.2%)
Flow of participants through trial
What is already known on this topic
Psychosocial treatment is generally effective for alcohol
dependence and misuse
A multicentre trial and meta-analyses showed that
motivational enhancement therapy, a brief psychosocial
treatment, is effective
Systematic reviews have shown that some treatments
involving members of the patient’s social network are also
effective
What this study adds
Social behaviour and network therapy did not differ in
effectiveness from motivational enhancement therapy
Both therapy groups reported substantial reductions in
drinking and associated problems and improved mental
health
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participants reported that the therapies were equally effective in
reducing drinking and associated problems and in improving
mental health.
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